Specifically, in ER-positive breast cancer cells, calcitriol and its analog EB1089 exert antiproliferative effects, partly by downregulating ERα levels, leading to the attenuation of estrogen-like responses [18,19,20]. Here, ESR1 is linked to breast carcinoma.